The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- VALUING AND ACCESSING MEDICINES
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- INDUSTRY REPUTATION
- INTERNATIONAL, TRADE AND IP
- HEALTH DATA
VALUING AND ACCESSING MEDICINES
Value and Access
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
R & D Manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
INTERNATIONAL, TRADE AND IP
International, trade and IP
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Industry’s proposals for a new Voluntary Scheme for Pricing, Access and Growth (VPAG)
The Association of the British Pharmaceutical Industry (ABPI) has published the industry’s vision for a new agreement with the government which will deliver for patients, the NHS and the economy.Read our proposal for the new Voluntary Scheme on branded medicines
Call for urgency to deliver on global pledge for antibiotic incentives
A new report, ‘Incentivising new antibiotics’ by the Office of Health Economics (OHE)
MMIP chair responds to Life Sciences Innovative Manufacturing Fund grants announcement
The government has announced the winners of the first tranche of Life Sciences Innovative Manufacturing Fund (LSIMF) grants.
ABPI welcome the appointment of Sir Hugh Taylor to key role in Voluntary Scheme negotiations
Sir Hugh Taylor has been appointed as Chief Advisor to the government on the Voluntary Scheme Negotiations.
ABPI response to MHRA clinical trials framework
The Medicines and Healthcare products Regulatory Agency (MHRA), in partnership with the Health Research Authority (HRA), has announced a new regulatory framework for clinical trials in the UK.
Latest blogs and events
ABPI Annual Conference 2023: Growing the UK as a Global Hub for Life Sciences
ABPI’s flagship annual conference is taking place on 27 April 2023, we are pleased to announce that registration is now open!
Medics 4 Rare Diseases: We need services to diagnose people earlier so they can have access to treatments
Dr Lucy McKay is the Chief Executive of Medics 4 Rare Diseases. She explains how training for healthcare professionals can help to unlock the potential of the Rare Disease Framework, while also stressing the importance of screening and access to treatments.
Ask your doctor about participating in a clinical trial, says Dr Catherine Bagot
Dr Catherine Bagot is a consultant haematologist who works in the West of Scotland Adult Haemophilia Comprehensive Care Centre. She talks about how treatments for haemophilia have evolved in recent years and why people with haemophilia should ask about participating in clinical trials.
A Breath of Fresh Air: A Welsh project to improve management of Cystic Fibrosis
Cendl Xanthe talks about her remote health monitoring study for people with Cystic Fibrosis (CF), and the importance of people with rare diseases taking part in clinical trials.
Key content hubs
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
The report covers how incentives can drive the development of new antibiotics which can help to address the challenges of #AMR.— ABPI (@ABPI_UK) March 31, 2023
Building on ABPI’s Dr Amit Aggarwal’s recent discussion on the #AntimicrobialResistance pilot, a new report from @OHENews analyses the learnings from the #AMR pilot🦠1/2 pic.twitter.com/O9CFl75biY— ABPI (@ABPI_UK) March 31, 2023
Great new report on #AMR from @OHENews https://t.co/axnWRruAr8— Richard Torbett (@TorbettR) March 30, 2023
📢Nearly 200 charities from @Cancer52org, @BloodCancerA & The Charity Medicines Access Coalition, are calling for 6 key tests to be met to ensure the next #VPAS is a success.— AlzheimersResearchUK 🍊 (@AlzResearchUK) March 30, 2023
Details below 👇https://t.co/Rva4eUizAS
The Pharmaceutical Industry in the UK
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.